Justice Department Tells Vanda It Is Weighing A Civil Complaint Over HETLIOZ Practices

Vanda also lost its HETLIOZ patent suits in Delaware and set a November 2027 generic entry date for Fanapt, its 10-Q shows.

Share
Justice Department Tells Vanda It Is Weighing A Civil Complaint Over HETLIOZ Practices

The Justice Department told Vanda Pharmaceuticals in October that it is considering a civil complaint over the company's historical HETLIOZ practices, according to a 10-Q filed Thursday. Vanda, a biopharmaceutical company that sells the schizophrenia drug Fanapt, the sleep-disorder drug HETLIOZ and the multiple sclerosis drug PONVORY, says no complaint has been filed.

A False Claims Act inquiry moves forward

The notice follows a Civil Investigative Demand the Justice Department sent in October 2024 as part of an investigation of possible False Claims Act violations. It sought documents on HETLIOZ practices; Vanda says it complied fully with that demand and with a later request for testimony.

Should the government sue, Vanda says it will contest every allegation. It says it cannot predict the timing of any proceeding. The prior quarter's 10-Q did not carry this passage.

HETLIOZ patent suits lose in Delaware

In September, the Delaware federal court granted summary judgment of non-infringement to Teva and Apotex on the '129 and '556 patents, relying partly on a June 2026 Supreme Court decision in Hikma v. Amarin. Vanda says it is evaluating future options.

In a separate Fanapt settlement in October, Vanda granted Alembic a non-exclusive license to sell a generic version in the U.S. from November 2, 2027, when the '610 patent expires.

HETLIOZ sales and the cash balance

HETLIOZ net sales fell 21% to $43.2 million for the first nine months. The company says they may decline in future periods, potentially significantly, because of generic competition. Third-quarter HETLIOZ sales of $21.7 million included about $7.0 million for orders shipped June 29 that arrived July 1.

Total revenue rose 24% to $69.8 million in the quarter, led by Fanapt at $38.8 million. Cash and marketable securities stood at $140.5 million, against $263.8 million at December 31, 2025. Vanda says that is enough for at least the next 12 months, and it expects full-year 2026 revenue above $240 million, according to its earnings release.

The FDA hearing on HETLIOZ for jet lag disorder is scheduled for December 14 to 18, 2026, and the FDA's target decision date on Quimilza is December 12.

Sources

More on Vanda Pharmaceuticals

All Vanda Pharmaceuticals (VNDA) coverage →